Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1043-1053. doi: 10.1051/medsci/2019228. Epub 2020 Jan 6.

[Antibody-drug conjugates in oncology. New strategies in development].

[Article in French; Abstract available in French from the publisher]

Author information

1
Institut de Recherche Pierre Fabre, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien-en-Genevois, France.
2
Cancer Research Center of Lyon (CRCL), Inserm 1052/CNRS, 69000 Lyon, France - Université de Lyon, 69000 Lyon, France - Hospices Civils de Lyon, 69000 Lyon, France.
3
GICC EA7501, Université de Tours, équipe IMT, 31 avenue Monge, 37200 Tours, France.

Abstract

in English, French

An Antibody-Drug Conjugate (armed antibody) is a vectorized chemotherapy that results from the grafting of a cytotoxic agent on a monoclonal antibody via a judiciously designed spacer arm. ADCs have made considerable progress in 10 years. In 2009, only gemtuzumab ozogamicin (Mylotarg®) was used clinically. In 2019, 4 other ADCs have been approved and more than 80 others are in active clinical trials. The second part of this review will focus on new emerging strategies to address ADCs drawbacks and attempt to broaden their therapeutic window. Finally, combinations with conventional chemotherapy or checkpoint inhibitors will be discussed, in the pursuit to make Antibody-Drug Conjugates the embodiment of Paul Ehrlich's dream of the magic bullet.

PMID:
31903916
DOI:
10.1051/medsci/2019228

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center